Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

5.66USD
21 Jul 2017
Change (% chg)

$-0.24 (-4.07%)
Prev Close
$5.90
Open
$5.94
Day's High
$5.99
Day's Low
$5.47
Volume
689,236
Avg. Vol
555,844
52-wk High
$8.03
52-wk Low
$1.51

Select another date:

Tue, May 30 2017

BRIEF-Immunogen and Sanofi amend license agreements

* Immunogen - co, affiliate of Sanofi have amended their license agreements covering all compounds in development by sanofi using Immunogen's technology

ImmunoGen drug moving ahead in single-agent, combination trials

Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.

ImmunoGen drug moving ahead in single-agent, combination trials

May 17 Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy.

BRIEF-Immunogen reports Q1 loss per share of $0.20

* Immunogen reports recent progress and first quarter 2017 operating results

BRIEF-Highbridge Capital Management reports 5.34 pct passive stake in Immunogen

* Highbridge Capital Management Reports 5.34 pct passive stake in Immunogen Inc as of April 13 Source text: (http://bit.ly/2opbbaB) Further company coverage:

BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate

* Immunogen has elected not to exercise its late stage co-development option for the us-market with Biotest's antibody-drug conjugate (BT-062) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Immunogen files for mixed shelf of up to $200 mln – SEC filing

* Immunogen Inc files for mixed shelf of up to $200 million – sec filing Source text for Eikon: Further company coverage:

BRIEF-Immunogen sees FY 2017 revenue $70 mln to $75 mln

* Immunogen reports recent progress and operating results for six-month period and quarter ended December 31, 2016

BRIEF-ImmunoGen announces first patient dosed in phase 3 study of mirvetuximab soravtansine in platinum-resistant ovarian cancer

* ImmunoGen announces first patient dosed in forward I Phase 3 study of mirvetuximab soravtansine in platinum-resistant ovarian cancer Source text for Eikon: Further company coverage:

BRIEF-Immunogen announces departure of Sandra Poole

* Poole, executive vice president, technical operations and commercial development, will leave company at end of January Source text for Eikon: Further company coverage:

Select another date: